review Open AccessTop 1% cited
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Annals of Oncology · 2018 · Vol. 30(1) · pp. 44–56
Timothy A. Chan✉(Memorial Sloan Kettering Cancer Center)Mark Yarchoan(Sidney Kimmel Comprehensive Cancer Center)Elizabeth M. Jaffee(Sidney Kimmel Comprehensive Cancer Center)Charles Swanton(The Francis Crick Institute)Sergio A. Quezada(University College London)Albrecht Stenzinger(University Hospital Heidelberg)Solange Peters✉(University Hospital of Lausanne)
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCancer Genomics and DiagnosticsMedicineImmunotherapyOncologyBiomarkerInternal medicinePrecision oncologyCancerGenetics
MeSH terms
Antineoplastic Agents, ImmunologicalHumansImmunotherapyMutationNeoplasmsPrognosisBiomarkers, Tumor
Funding
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Celgene
- F. Hoffmann-La Roche
- Exelixis
- Servier
- National Institutes of Health
- Genentech
- Chugai Pharmaceutical
- Foundation Medicine
- National Cancer Institute
Citations
2,846
FWCI
81.19
field-weighted impact
References
112
Percentile
100%
vs. same field & year
Citations per year
Cited by
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
Annals of Oncology · 2021 · 1,029 citations
References
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
New England Journal of Medicine · 2015 · 9,308 citations
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Journal of Clinical Oncology · 2010 · 2,913 citations
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Immunity · 2004 · 2,953 citations
The immune contexture in human tumours: impact on clinical outcome
Nature reviews. Cancer · 2012 · 4,857 citations
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Science · 2015 · 7,864 citations
The blockade of immune checkpoints in cancer immunotherapy
Nature reviews. Cancer · 2012 · 13,550 citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
New England Journal of Medicine · 2010 · 15,037 citations
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 9,391 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.